News

The Max SoloStar from Sanofi is capable of carrying 300 units/mL of insulin glargine, and administer 160 units/mL in a single injection.

Results contradicted previous studies that did not account for baseline differences between DAA- and interferon-treated patients.

How the nation’s excessive spending and poor health outcomes drove researchers to seek solutions.

The update includes significant changes in the management of this infection and reflects the evolving controversy over best methods for diagnosis.

AbbVie won’t seek accelerated approval for Rovalpituzumab Tesirine in third-line relapsed/refractory small cell lung cancer due to the low percentages in efficacy in the TRINITY study.

Researchers in Pennsylvania want to bolster the scientific case for the use of medical marijuana as an alternative to opioids.

This morning, Protagonist Therapeutics announced that the Phase 2b PROPEL study of PTG-100 in patients with ulcerative colitis has been discontinued.

The first comprehensive examination of cortical brain volume in preschool children with ADHD indicates that anomalous brain structure is evident in early development stages.

A recent study suggests low doses of oral cyclosporine A do not prevent second-eye involvement in adult patients with unilateral Leber’s hereditary optic neuropathy (LHON).

Amid the vaccine reluctance movement, new data show that pediatric patients with ASD and their siblings are less likely to have their full vaccinations, making them susceptible to preventable illness.

Data presented at the 16th International Symposium on Amyloidosis in Japan were presented this morning, showing that inotersen-treated patients with hATTR amyloidosis continued to exhibit sustained benefit.

The emergency department may provide an opportunity to capture patients with undiagnosed HIV infection missed by clinic-based screening programs.

Although LY2828360 failed as a therapeutic option for osteopathic pain in phase 2, it may be granted new life as a neuropathic pain treatment.

Robert Redfield has years of experience as a clinician and researcher, but lacks public health credentials.

A new study helps explain why African-American and Puerto Rican children don’t respond as well to the common asthma drug, albuterol.

Developers hope the beta-3 agonist can report consistent efficacy and tolerability.

The approved use of a direct-acting antiviral combination for 8 weeks to treat HCV genotypes 1 and 3 was supported by data from over 1200 patients.

The first-of-its-kind research links inhaled corticosteroids to adrenal suppression in asthma and chronic obstructive pulmonary disease patients who have a genetic variant in the PDGFD gene.

Data from a Phase 2 study suggests that voxtalisib has a promising safety profile, but might not be as effective in patients with aggressive malignancies as it is in patients with follicular lymphoma.

A Phase 2a clinical study evaluating Molgradex was recently initiated by Savara, Inc. The study intends to evaluate the reduction of sputum samples without growth of non-tuberculosis mycobacteria during the treatment period.

Positive data was anounced regarding PBI-4050, a possible treatment for Alström syndrome.

In February, the U.S. FDA accepted the New Drug Application for migalastat, a potential Fabry disease therapy in development by Amicus. This morning, it was announced that it was approved in Japan.

A team of researchers have found that targeting the MLH3 protein involved in DNA repair can reduce the GAA repeat expansion that results in Friedreich's ataxia

Symptom burden may be exacerbated after menopause, supporting a shifting paradigm for HIV care management.

According to the investigators, this is the first time a consistent and dramatic global effect on antisense transcription has been associated with a disease state in humans.

Integrating transgender-specific content into medical curricula improves student knowledge and comfort with transgender medical care.

Participants taking anti-depressants 36% more likely to develop atrial fibrillation.

This new infographic from Rare Disease Report provides 5 little-known facts about the Huntington's disease that might not necessarily be covered in news articles.

The U.S. FDA has expanded the approval for nilotinib to include the treatment of first- and second-line pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).

As those age 65 and older face more serious illness, unprecedented burdens to serve a burgeoning population in need of high quality, coordinated care outside the acute care setting have emerged.